ELECT: A phase 3 study of efficacy and safety of lanreotide autogel/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs)

被引：11
|
作者：
Vinik, Aaron
Wolin, Edward M.
Audry, Helene
Gomez-Panzani, Edda L.
机构：
[1] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] Ipsen, Boulougne Billancourt, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.268
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
268
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Lanreotide Autogel/Depot (LAN) Post-Octreotide Long-Acting Release (OCT) for Safe and Tolerable Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 12 - 13
  • [42] Lanreotide Autogel/Depot (LAN) Post-Octreotide Long-Acting Release (OCT) for Safe and Tolerable Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Saif, M. Wasif
    Fu, Julie
    Smith, Melissa
    Maloney, Antonia
    Relias, Valerie
    JWeinstein, Barbara
    Suarez, Yvelisse N.
    Goodman, Martin D.
    Daly, Kevin P.
    PANCREAS, 2017, 46 (03) : 436 - 436
  • [43] Safety and Efficacy of Lanreotide Depot Versus Placebo in Neuroendocrine Tumor Patients With a History of Carcinoid Syndrome and Prior Octreotide Therapy
    Fisher, George A., Jr.
    Wolin, Edward M.
    Kunz, Pamela
    Liyanage, Nilani
    Gomez-Panzani, Edda
    Lowenthal, Susan Pitman
    Pommier, Rodney F.
    Shaheen, Montaser
    Vinik, Aaron
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S1007 - S1007
  • [44] Efficacy and Safety of Lanreotide Depot vs Placebo in Patients With Neuroendocrine Tumor and a History of Carcinoid Syndrome and Prior Octreotide Therapy
    Fisher, George A., Jr.
    Wolin, Edward M.
    Kunz, Pamela
    Liyanage, Nilani
    Gomez-Panzani, Edda
    Lowenthal, Susan Pitman
    Pommier, Rodney F.
    Shaheen, Montaser
    Vinik, Aaron
    PANCREAS, 2016, 45 (03) : 475 - 475
  • [45] Effects of lanreotide autogel/depot (LAN) in patients with neuroendocrine tumors (NETs) age 65 or younger versus older than age 65: Subgroup analyses from the CLARINET study.
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [46] Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study.
    Pommier, Rodney F.
    Fisher, George A.
    Wolin, Edward M.
    Kunz, Pamela L.
    Liyanage, Nilani
    Lowenthal, Susan W. Pitman
    Mirakhur, Beloo
    Shaheen, Montaser F.
    Vinik, Aaron
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [47] Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/ Depot (LAN) for Patients with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
    Pavel, M.
    Dromain, C.
    Majdi, A.
    Houchard, A.
    NEUROENDOCRINOLOGY, 2017, 105 : 204 - 204
  • [48] Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) vs. Placebo in Patients with Enteropancreatic Neuroendocrine Tumors: Results From the CLARINET Core Study
    Ruszniewski, Philippe
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    PANCREAS, 2015, 44 (02) : 357 - 357
  • [49] Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study.
    Caplin, Martyn E.
    Ruszniewski, Philippe B.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wall, Lucy R.
    Rindi, Guido
    Langley, Alison
    Blumberg, Joelle
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results
    Pavel, M.
    Cwikla, J. B.
    Lombard-Bohas, C.
    Borbath, I
    Shah, T.
    Pape, U. F.
    Thanh, Truong X. M.
    Houchard, A.
    Ruszniewski, P.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 143 - 143
12345